30 May 2024

Implementation scientists working to improve newborn screening

blood is taken from a two week old baby to test for phenylketonuria

A dedicated team of implementation scientists, including Director of SPHERE's Implementation Science Collaborative, Natalie Taylor, IS Collaborative member, Carolyn Mazariego-Jones, PhD, and Zhicheng Li, ran an innovative workshop in Queensland in May. The focus? Transforming the consent process for newborn bloodspot screening (NBS) to enhance newborn screening practices and pave the way for healthier futures.

The Importance of Newborn Bloodspot Screening NBS

Newborn bloodspot screening is a critical component of early disease detection. By analysing a small blood sample taken from a baby’s heel shortly after birth, potential health conditions can be identified early on. These conditions may include metabolic disorders, genetic diseases, and endocrine disorders. Early detection allows for timely interventions, leading to better health outcomes.

The Importance of Consent in the NBS space

Informed consent plays a crucial role in newborn bloodspot screening, especially as the field evolves to incorporate genomic information. Why does consent matter?

  • Respecting Autonomy: Informed consent respects the autonomy of parents and their newborns. 
  • Understanding Risks and Benefits: Newborn screening involves testing for various conditions shortly after birth. Parents need to understand the purpose, benefits, and potential risks of these tests. 
  • Genomic Complexity: Genomic screening provides insights into an individual’s genetic makeup. While it can identify potential health risks, it may also reveal variants of uncertain significance or incidental findings.
  • Privacy and Data Sharing: Genomic information is sensitive. Parents should know how their child’s data will be stored, shared, and used.
  • Future Uses: Beyond immediate screening, genomic data may have future applications (e.g., research, personalized medicine). 

"Informed consent empowers parents to make informed decisions about newborn screening, including the incorporation of genomic information. It respects autonomy, promotes transparency, and safeguards privacy. As technology advances, maintaining robust consent processes remains essential for ethical and responsible healthcare practices," said A/Prof Taylor.

Bringing Together Key Stakeholders

At the heart of the efforts are 65 key stakeholders from various fields, including healthcare professionals, researchers, policymakers, and community advocates. By collaborating and sharing insights, they aim to bridge the gap between research and practice, ensuring that every newborn receives the best possible care.

A Transformative Grant

The project is part of a transformative grant funded by the Medical Research Future Fund (MRFF). The project will explore innovative approaches, collaborate with experts, and drive positive change in NBS practices to help make a lasting impact on the health and well-being of newborns across Queensland and beyond.

Share and Print


For news and media, please contact

[email protected]